Literature DB >> 6442232

Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.

G Cohen, P Pasik, B Cohen, A Leist, C Mytilineou, M D Yahr.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6442232     DOI： 10.1016/0014-2999(84)90700-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


× No keyword cloud information.
  28 in total

1.  Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.

Authors:  Matthias Löhle; Heinz Reichmann
Journal:  BMC Neurol       Date:  2011-09-22       Impact factor: 2.474

2.  The effects of deprenyl on methamphetamine-induced dopamine depletions.

Authors:  S K Johnson; D Medina; G C Wagner
Journal:  J Neural Transm Gen Sect       Date:  1992

3.  The effect of long-term treatment with deprenyl on basal and L-dopa evoked dopamine release in vitro from the corpus striatum of aged rats.

Authors:  D E Dluzen; J L McDermott
Journal:  J Neural Transm Gen Sect       Date:  1991

Review 4.  Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.

Authors:  H M Bryson; R J Milne; P Chrisp
Journal:  Pharmacoeconomics       Date:  1992-08       Impact factor: 4.981

Review 5.  Early detection of Parkinson's disease. Implications for treatment.

Authors:  R Di Paola; R J Uitti
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

Review 6.  Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.

Authors:  Éva Szökő; Tamás Tábi; Peter Riederer; László Vécsei; Kálmán Magyar
Journal:  J Neural Transm (Vienna)       Date:  2018-02-07       Impact factor: 3.575

Review 7.  A scientific rationale for protective therapy in Parkinson's disease.

Authors:  C W Olanow
Journal:  J Neural Transm Gen Sect       Date:  1993

8.  Neurotoxic damage to the nigrostriatal system in rats following intranigral administration of MPDP+ and MPP+.

Authors:  C J Sun; J N Johannessen; W Gessner; I Namura; W Singhaniyom; A Brossi; C C Chiueh
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

9.  Effects of deprenyl on monoamine oxidase and neurotransmitters in the brains of MPTP-treated aging mice.

Authors:  M Gupta; H L Wiener
Journal:  Neurochem Res       Date:  1995-04       Impact factor: 3.996

Review 10.  Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.

Authors:  P Chrisp; G J Mammen; E M Sorkin
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.